Brief: Hyundai Bioscience Announces Successful Result From Preclinical Study Of Niclosamide-Based Oral Anticancer Drug
22/04/2024 10:58
April 22 (Reuters) - Hyundai Bioscience Co Ltd
048410.KQ :
* HYUNDAI BIOSCIENCE ANNOUNCES ITS SUCCESSFUL RESULT FROM A
PRECLINICAL STUDY OF A NICLOSAMIDE-BASED ORAL ANTICANCER DRUG TO
TREAT TRIPLE-NEGATIVE BREAST CANCER
Source text for Eikon: ID:nPnYJLgSa
Further company coverage: 048410.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hyundai Bioscience Co
See all newsBrief: Hyundai Bioscience Announces Successful Result From Preclinical Study Of Niclosamide-Based Oral Anticancer Drug
S.Korean vaccine firm SK Bioscience sees shares soar 30% on debut (updated)
Vaccine developer SK Bioscience to raise $1.3 bln in S.Korea's largest IPO since 2017 (updated)
Brief: Hyundai Bioscience Develops Injection Drug For Potential Treatment Of Severe Cases Of COVID-19
Brief: Hyundai Bioscience Says Co's COVID-19 Oral Drug Solved Niclosamide's Inhibitory Concentration Problem